CSIMarket
 


Fibrogen Inc   (NASDAQ: FGEN)
Other Ticker:  
 
 

FGEN's Net Income Growth by Quarter and Year

Fibrogen Inc 's Net Income results by quarter and year

 



FGEN Net Income (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December - 17.98 -56.23 -66.18
3rd Quarter September - -17.08 -63.62 -91.65
2nd Quarter June - -15.54 -87.68 -72.62
1st Quarter March 4.64 -32.93 -76.71 -63.21
FY   4.64 -47.57 -284.24 -293.66

FGENs Annual Net Income
Fibrogen Inc 's Net Income in the fiscal year 2024 $ -47.58 millions
Fibrogen Inc 's Net Income in the fiscal year 2023 $ -284.23 millions
Fibrogen Inc 's Net Income in the fiscal year 2022 $ -293.65 millions
Fibrogen Inc 's Net Income in the fiscal year 2021 $ -290.02 millions
Fibrogen Inc 's Net Income in the fiscal year 2019 $ -76.97 millions




FGEN Net Income first quarter 2025 Y/Y Growth Comment
Fibrogen Inc in the first quarter 2025 achieved Net Income of $ 4.64 millions compare to net loss recorded in same quarter a year ago.

Looking into first quarter 2025 results within Major Pharmaceutical Preparations industry 29 other companies have achieved higher Net Income growth. While Fibrogen Inc ' s Net Income no change of % ranks overall at the positon no. 1390 in the first quarter 2025.




FGEN Net Income ( Y/Y Growth %) 2025
2024 2023 2022
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   - - - -

Financial Statements
Fibrogen Inc 's first quarter 2025 Net Income $ 4.64 millions FGEN's Income Statement
Fibrogen Inc 's first quarter 2024 Net Income $ -32.93 millions Quarterly FGEN's Income Statement


FGEN Net Income (Quarter on Quarter Growth %)

2025
2024 2023 2022
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March -74.2 % - - -
FY (Year on Year)   - - - -




Net Income first quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #30
Healthcare Sector #103
Overall #1390

Net Income Y/Y Growth Statistics
High Average Low
-74.2 % -74.2 % -74.2 %
(Mar 31 2025)  
Net Income first quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #30
Healthcare Sector #103
Overall #1390
Net Income Y/Y Growth Statistics
High Average Low
-74.2 % -74.2 % -74.2 %
(Mar 31 2025)  

Net Income by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Fibrogen Inc 's Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
-74.2 % -74.2 % -74.2 %
(Mar 31 2025)  


FGEN's I. Quarter Q/Q Net Income Comment
In the I. Quarter 2025 Fibrogen Inc realized fall in Net Income from the fourth quarter by -74.2% to $ 4.64 millions, from $ 17.98 millions achived a quarter before.

Within Major Pharmaceutical Preparations industry 29 other companies have achieved higher Net Income quarter on quarter growth. While Fibrogen Inc 's Net Income growth quarter on quarter, overall rank is 1390.


Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #30
Healthcare Sector #103
Overall #1390
Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #30
Healthcare Sector #103
Overall #1390
Net Income Q/Q Growth Statistics
High Average Low
-74.2 % -74.2 % -74.2 %
(Mar 31 2025)  


FGEN's I. Quarter Q/Q Net Income Comment
In the I. Quarter 2025 Fibrogen Inc disclosed fall in Net Income from the previous quarter by -74.2% to $ 4.64 millions, from $ 17.98 millions declared in the previous reporting period.

Within Major Pharmaceutical Preparations industry 29 other companies have achieved higher Net Income quarter on quarter growth. While Fibrogen Inc 's Net Income growth quarter on quarter, overall rank is 1390.


Fibrogen Inc 's 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Mar 31 2025)
12 Months Ending
(Dec 31 2024)
12 Months Ending
(Sep 30 2024)
12 Months Ending
(Jun 30 2024)
12 Months Ending
(Mar 31 2024)
Cumulative Net Income 12 Months Ending $ -10.01 $ -47.58 $ -121.79 $ -168.32 $ -240.46
Y / Y Net Income Growth (TTM) - - - - -
Year on Year Net Income Growth Overall Ranking # # # # #
Seqeuential Net Income Change (TTM) - - - - -
Seq. Net Income Growth (TTM) Overall Ranking # # # # #


Cumulative Net Income growth Comment


Fibrogen Inc achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Net Income growth Comment


Fibrogen Inc achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .


Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Net Income Growth
Major Pharmaceutical Preparations Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
FGEN's Net Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for FGEN's Competitors
Net Income Growth for Fibrogen Inc 's Suppliers
Net Income Growth for FGEN's Customers

You may also want to know
FGEN's Annual Growth Rates FGEN's Profitability Ratios FGEN's Asset Turnover Ratio FGEN's Dividend Growth
FGEN's Roe FGEN's Valuation Ratios FGEN's Financial Strength Ratios FGEN's Dividend Payout Ratio
FGEN's Roa FGEN's Inventory Turnover Ratio FGEN's Growth Rates FGEN's Dividend Comparisons



Companies with similar Net Income fall for the quarter ending Mar 31 2025 within Healthcare SectorY/Y Change %Net Income for the quarter ending Mar 31 2025
Pfizer Inc-4.80%$ -4.803 millions
Abbvie Inc -6.05%$ -6.050 millions
Incyte Corporation-6.69%$ -6.691 millions
Labcorp Holdings Inc -6.70%$ -6.702 millions
Mettler Toledo International Inc-7.84%$ -7.843 millions
National Research Corporation-9.00%$ -8.995 millions
Progyny Inc -10.88%$ -10.883 millions
Align Technology inc -11.23%$ -11.233 millions
Iqvia Holdings Inc -13.54%$ -13.542 millions
Ani Pharmaceuticals Inc-13.87%$ -13.874 millions
Stryker Corp-17.01%$ -17.005 millions
Embecta Corp -18.69%$ -18.685 millions
West Pharmaceutical Services Inc -22.12%$ -22.116 millions
Utah Medical Products Inc-23.13%$ -23.129 millions
Envista Holdings Corporation-23.73%$ -23.729 millions
Davita Inc -24.11%$ -24.107 millions
Mimedx Group Inc -24.17%$ -24.166 millions
Carlisle Companies Incorporated-25.48%$ -25.481 millions
Corcept Therapeutics Inc-26.26%$ -26.263 millions
Dexcom Inc -28.01%$ -28.005 millions
Insulet Corporation-31.26%$ -31.262 millions
Select Medical Holdings Corp-36.22%$ -36.218 millions
Biogen Inc -38.87%$ -38.866 millions
Alkermes Plc -39.00%$ -39.003 millions
Vertex Pharmaceuticals Inc-41.22%$ -41.224 millions
Amphastar Pharmaceuticals Inc -41.44%$ -41.439 millions
Solventum Corporation-42.19%$ -42.194 millions
Becton Dickinson And Company-42.64%$ -42.644 millions
Lantheus Holdings Inc -44.34%$ -44.345 millions
Pacira Biosciences inc -46.41%$ -46.408 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com